Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma
Closing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.
CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma
Naresh Bumma, MD, reviews how he selects between CAR T-cell therapy and bispecific agents for patients with refractory multiple myeloma.
Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma
Naresh Bumma, MD, details other bispecific agents on the horizon for relapsed multiple myeloma treatment.
Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma
Abdullah Khan, MBBS, explains the current data on bispecific T-cell engaging antibodies for the treatment of relapsed multiple myeloma.
Available Treatment Options for Patients with Relapsed Multiple Myeloma
Ashley Rosko, MD, presents the case of a 72-year-old woman with relapsed multiple myeloma for discussion.
Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM
April Logue, APRN-CNP, shares her perspective on selecting between doublet and triplet regimens for patients with transplant-ineligible newly-diagnosed multiple myeloma.
Data Updates on the Treatment of Transplant-Ineligible NDMM From the MAIA Trial
Naresh Bumma, MD, reviews updated data from the MAIA trial in transplant-ineligible newly-diagnosed multiple myeloma.
First-Line Treatment Options for Patients With Transplant-Ineligible NDMM
Ashley Rosko, MD, presents the case of a 79-year-old female with transplant-ineligible newly-diagnosed multiple myeloma.
Treatment Considerations for Patients with High-Risk NDMM
Barry Hammer, PA-C, defines high-risk multiple myeloma and explains the treatment adjustments needed for newly-diagnosed patients.
The Importance of Access to Care for Multiple Myeloma in Community Settings
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
CARE Clinic Uses Multidisciplinary Approach For Geriatric Multiple Myeloma
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
Using ‘Intensity’ to Gain ‘Deep Control’ in Myeloma at Ohio State
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.
BiTE Therapy May Impact Standard of Care in Multiple Myeloma, Expert Says
Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.
Transplant Eligibility in Patients With NDMM
Naresh Bumma, MD, reviews data from the final analysis of the GRIFFIN trial investigating a quadruplet induction therapy regimen in newly-diagnosed multiple myeloma and discusses how patients are evaluated for transplant.
Treatment Approaches for Patients With Newly-Diagnosed Multiple Myeloma (NDMM)
Ashley Rosko, MD, presents the case of a 57-year-old male with newly-diagnosed multiple myeloma for discussion.
Treating Older Patients With Myeloma: Is Frailty More Important Than Age?
In this peer-to-peer discussion two experts discuss the nuances and challenges of treating elderly patients with myeloma, and why therapies need to be tailored based on frailty status rather than age.
